Protein Profiling, Unleashed
Nomic Bio is redefining proteomics, their scalable, automated platform unlocks deep, proteome-wide insights, enabling faster biomarker discovery, drug development, and diagnostics. With a productized, commercial platform and strong pharma partnerships, Nomic is setting the new standard for proteomics at scale.
Proteomics has lagged behind
Proteomics has long been the missing link in biology, essential but hard to access. Traditional tools are slow, complex, and costly, limiting their use in real-world drug development. The industry needs a scalable, practical solution to bring protein-level insight into everyday discovery workflows.
Proteomics at scale
Nomic’s proprietary nELISA technology combines precision measurement with scalable throughput and robust analytics, bringing proteomics to the same level of accessibility and utility as genomics. Their AI-driven approach enables customers to discover, validate, and act on protein-based biomarkers faster than ever.
Partners in growth, aligned in purpose
AVANT participated in Nomic’s oversubscribed $42 million Series B funding round at a pivotal growth stage to accelerate commercial traction, enabling design-in with top biopharma customers. We bring strategic capital, operational expertise, and a shared vision to help make proteomics a foundational layer in the next generation of drug discovery.
Proteomics has lagged behind
Proteomics has long been the missing link in biology, essential but hard to access. Traditional tools are slow, complex, and costly, limiting their use in real-world drug development. The industry needs a scalable, practical solution to bring protein-level insight into everyday discovery workflows.
Proteomics at scale
Nomic’s proprietary nELISA technology combines precision measurement with scalable throughput and robust analytics, bringing proteomics to the same level of accessibility and utility as genomics. Their AI-driven approach enables customers to discover, validate, and act on protein-based biomarkers faster than ever.
Partners in growth, aligned in purpose
AVANT participated in Nomic’s oversubscribed $42 million Series B funding round at a pivotal growth stage to accelerate commercial traction, enabling design-in with top biopharma customers. We bring strategic capital, operational expertise, and a shared vision to help make proteomics a foundational layer in the next generation of drug discovery.